These studies suggest that therapeutic CD47 antibodies and SIRPα decoys intended to block SIRPα signaling in innate immune cells could also alter CD47 signaling in cancer cells in a manner that provides therapeutic benefits. This evidence concerns the gene CD47 and cancer.